Browsing NTU Scholars | NTU Scholars

Showing results 1 to 20 of 50 next >

Issue Date	Title	Author(s)	Source	scopus	WOS
2011	Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells	Chen K.-F.; Chen H.-L.; Tai W.-T.; Feng W.-C.; CHIH-HUNG HSU ; PEI-JER CHEN ; ANN-LII CHENG	Journal of Pharmacology and Experimental Therapeutics	248	246
2015	Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A	Chao T.-T.; Wang C.-Y.; Chen Y.-L.; Lai C.-C.; Chang F.-Y.; Tsai Y.-T.; Chao C.-H.H.; Shiau C.-W.; Huang Y.-C.T.; CHONG-JEN YU ; Chen K.-F.	Oncotarget	40	37
2018	Antagonizing SET augments the effects of radiation therapy in hepatocellular carcinoma through reactivation of PP2A-Mediated akt downregulation	CHAO YUAN HUANG ; Hung M.-H.; Shih C.-T.; Hsieh F.-S.; Kuo C.-W.; Tsai M.-H.; Chang S.-S.; Hsiao Y.-J.; Chen L.-J.; Chao T.-I.; Chen K.-F.	Journal of Pharmacology and Experimental Therapeutics	9	8
2012	Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity	Chen K.-F.; Tai W.-T.; Hsu C.-Y.; Huang J.-W.; Liu C.-Y.; PEI-JER CHEN ; Kim I.; Shiau C.-W.	European Journal of Medicinal Chemistry	61	61
2012	Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A	CHAO YUAN HUANG ; CHIA-CHENG WEI ; Chen K.-C.; Chen H.-J.; ANN-LII CHENG ; Chen K.-F.	Cancer Letters	26	26
2009	Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway	Chen K.-F.; Yeh P.-Y.; CHIUN HSU ; CHIH-HUNG HSU ; YEN-SHEN LU ; Hsieh H.-P.; PEI-JER CHEN ; ANN-LII CHENG	Journal of Biological Chemistry	89	84
2011	Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A	Chen K.-F.; Yu H.-C.; Liu C.-Y.; Chen H.-J.; Chen Y.-C.; Hou D.-R.; PEI-JER CHEN ; ANN-LII CHENG	Molecular Cancer Therapeutics	35	31
2019	Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced �]-catenin activation	Hung M.-H.; Chen Y.-L.; Chen L.-J.; Chu P.-Y.; Hsieh F.-S.; Tsai M.-H.; Shih C.-T.; Chao T.-I.; CHAO YUAN HUANG ; Chen K.-F.	Cell Death and Disease	30	28
2013	Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells	Liu C.-Y.; Shiau C.-W.; Kuo H.-Y.; HSIANG-PO HUANG ; Chen M.-H.; Tzeng C.-H.; Chen K.-F.	Haematologica	37	36
2013	Cancerous Inhibitor of Protein Phosphatase 2A Mediates Bortezomib-Induced Autophagy in Hepatocellular Carcinoma Independent of Proteasome	Yu H.-C.; Hou D.-R.; Liu C.-Y.; Lin C.-S.; Shiau C.-W.; ANN-LII CHENG ; Chen K.-F.	PLoS ONE	39	92
2010	CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells	Chen K.-F.; Liu C.-Y.; Lin Y.-C.; Yu H.-C.; TSUNG-HAO LIU ; Hou D.-R.; PEI-JER CHEN ; ANN-LII CHENG	Oncogene	140	133
2014	CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation	Wang C.-Y.; Chao T.-T.; Chang F.-Y.; Chen Y.-L.; Tsai Y.-T.; Lin H.-I.; Huang Y.C.T.; Shiau C.-W.; CHONG-JEN YU ; Chen K.-F.	Lung Cancer	25	23
2012	CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells	Lin Y.-C.; Chen K.-C.; CHING-CHOW CHEN ; ANN-LII CHENG ; Chen K.-F.	Oral Oncology	51	49
2018	Corrigendum to “Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity” (Eur. J. Med. Chem. (2012) 55 (220–227)(S0223523412004497)(10.1016/j.ejmech.2012.07.023))	Chen K.-F.; Tai W.-T.; Hsu C.-Y.; Huang J.-W.; Liu C.-Y.; PEI-JER CHEN ; Kim I.; Shiau C.-W.	European Journal of Medicinal Chemistry	1	1
2017	Corrigendum to “Degradation of Epidermal Growth Factor Receptor Mediates Dasatinib-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma Cells” [Neoplasia (United States) 14 (2012) 463–475](S1476558612801023)(10.1596/neo.12300)	Lin Y.-C.; Wu M.-H.; TZU-TANG WEI ; Chuang S.-H.; Chen K.-F.; ANN-LII CHENG ; CHING-CHOW CHEN	Neoplasia (United States)	0	0
2017	Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047))	Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN ; Chen K.-F.	Journal of Hepatology	1	1
2017	Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2017) 66(3) (666–668) (S0168827816307127) (10.1016/j.jhep.2016.12.007))	Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN ; Chen K.-F.	Journal of Hepatology	0	1
2012	Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells	Lin Y.-C.; Wu M.-H.; TZU-TANG WEI ; Chung S.-H.; Chen K.-F.; ANN-LII CHENG ; CHING-CHOW CHEN	Neoplasia (United States)	36	36
2014	Discovery of novel src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma	Tai W.-T.; Shiau C.-W.; PEI-JER CHEN ; Chu P.-Y.; HSIANG-PO HUANG ; Liu C.-Y.; Huang J.-W.; Chen K.-F.	Hepatology	54	53
2016	Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis	Su J.-C.; Mar A.-C.; Wu S.-H.; Tai W.-T.; Chu P.-Y.; Wu C.-Y.; Tseng L.-M.; Lee T.-C.; Chen K.-F.; Liu C.-Y.; HAO-CHIEH CHIU ; Shiau C.-W.	Scientific Reports	35	29

Showing results 1 to 20 of 50 next >

DSpace CRIS

Browsing by Author Chen K.-F.